IPO Listed — 16 Oct 2025
Listing Price: ₹620
Rubicon Research IPO GMP History | Listing Price ₹620 & Kostak Rate
Rubicon Research IPO has been listed on October 16, 2025 at a listing price of ₹620, against the issue price of ₹485 — a gain of ₹135 (+27.84%). The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Rubicon Research IPO raised ₹1,378 Cr. through its IPO at a price band of ₹461 to ₹485 per share, with a lot size of 30 shares. The IPO was open for subscription from 09 Oct 2025 to 13 Oct 2025.
GMP Trend Chart
Day-wise GMP Trend
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| No GMP history available yet. | |||||
Rubicon Research IPO Dates
| Event | Date |
|---|---|
| Open Date | 09 Oct, 2025 |
| Close Date | 13 Oct, 2025 |
| Allotment Date | 14 Oct, 2025 |
| Refund Date | 15 Oct, 2025 |
| Credit to Demat | 15 Feb, 2026 |
| Listing Date | 16 Oct, 2025 |
Rubicon Research IPO Actual Listing Price
| Basis | Value |
|---|---|
| Issue Price | ₹485 |
| Actual Listing Price | ₹620 (+27.84%) |
| Listing Gain / Loss | +₹135 per share |
| Listing Date | 16 Oct, 2025 |
Is Rubicon Research IPO GMP Reliable?
Grey market premium for Rubicon Research IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- Cross-check before acting: Review the Rubicon Research IPO full review for a fundamentals-based assessment before making any grey market trades.
Rubicon Research IPO IPO Kostak Rate Explained
The Kostak rate for Rubicon Research IPO was not active during the subscription period, as no grey market premium was established. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not active for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Rubicon Research IPO
The company offers a range of pharmaceutical products, including oral solids, injectables, and other specialty formulations, targeting therapeutic segments such as central nervous system (CNS), cardiovascular, and oncology. Rubicon Research is promoted by experienced professionals with deep industry expertise, who have played a key role in shaping its growth strategy and global presence. Its business model is driven by product development partnerships, contract manufacturing, and direct sales in key markets, enabling it to generate revenue through both proprietary products and collaborations with global pharmaceutical companies.
Frequently Asked Questions about Rubicon Research IPO
What is the GMP of Rubicon Research IPO?
The current Grey Market Premium (GMP) of Rubicon Research IPO is not yet started or active in the market.
What is the Kostak Price of Rubicon Research IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Rubicon Research IPO is currently not available.
What is the Subject to Sauda Price of Rubicon Research IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is currently not available.
What was the actual listing price of Rubicon Research IPO?
Rubicon Research IPO listed on October 16, 2025 at ₹620, against the issue price of ₹485 — a gain of +27.84%.
How did the GMP of Rubicon Research IPO trend before listing?
The GMP of Rubicon Research IPO was stable in its final days before listing. View the day-wise table above for the complete GMP history.
Explore Rubicon Research IPO Further
For a complete picture before making your investment decision, explore these resources:
Discussion 0
No comments yet
Be the first to share your thoughts!